Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Donate to our blog

Your support will help Science & Enterprise continue to provide science news for business people and business news for scientists.

Drug Reconciliation Program Cuts Hospital Readmission

Consultations with pharmacists on medications when patients leave the hospital for home are shown to reduce the rate of readmission to the hospital by half. . . . → Read More: Drug Reconciliation Program Cuts Hospital Readmission

More Device Approvals, Higher Risks in Europe than U.S.

(PublicDomainPictures, Pixabay)

29 June 2016. An analysis of regulatory approvals and outcomes shows medical devices are reviewed and approved faster in Europe than the U.S., but also face more safety issues later on. A team from Kings College London and Harvard University published its findings yesterday in the journal BMJ.

Researchers led by Aaron . . . → Read More: More Device Approvals, Higher Risks in Europe than U.S.

New Diabetic Eye Disease Drugs Shown Not Cost-Effective

(TBIT/Pixabay)

10 June 2016. An evaluation of two new biologic drugs to treat diabetic macular edema, an eye disease caused by diabetes, show the drugs do not provide enough additional benefit over much less expensive treatments to justify their higher price tags. The team led by Adam Glassman of the Jaeb Center for Health . . . → Read More: New Diabetic Eye Disease Drugs Shown Not Cost-Effective

Kauffman Index Shows Higher Start-Up Growth in 2016

Top 40 metropolitan regions in the U.S. in rate of entrepreneurial growth. (Ewing Marion Kauffman Foundation)

8 June 2016. An index of high-growth start-up companies shows the rate of entrepreneurial expansion in the U.S. accelerated for the third year in a row, with greatest concentration of growing enterprises found in the Washington, D.C. region. . . . → Read More: Kauffman Index Shows Higher Start-Up Growth in 2016

Another Chance to Get Serious on Drug Pricing

Stephen Ubl at National Press Club, 25 May 2016 (A. Kotok)

Stephen Ubl, president and CEO of Pharmaceutical Research and Manufacturers of America, or PhRMA, told a press and industry event in Washington, D.C. on Wednesday (25 May) that drug makers are eager to develop more individualized treatments for patients, but proposed regulations on . . . → Read More: Another Chance to Get Serious on Drug Pricing

Pricing Factors Proposed for Gene Therapies

(NIH.gov)

Updated 27 May 2016. See Another Chance to Get Serious on Drug Pricing.

A pediatric cancer specialist and venture capital executive argue for establishing a framework for pricing gene therapies to treat inherited and other diseases, before these treatments are approved by FDA. Stuart Orkin, a pediatric oncologist and hematologist at Dana-Farber Cancer . . . → Read More: Pricing Factors Proposed for Gene Therapies

Braeburn to Continue N. Carolina Facility Despite HB2

(Boston Public Library, Wikimedia Commons)

17 May 2016. Braeburn Pharmaceuticals, a developer of treatments for opioid addiction, will continue with its plans to build a research and manufacturing facility in North Carolina, despite its opposition to a recent state law overturning local ordinances prohibiting discrimination against the LGBT (Lesbian, Gay, Bisexual and Transgender) individuals. . . . → Read More: Braeburn to Continue N. Carolina Facility Despite HB2

Drug Pricing Reform Even Big Pharma Might Like

(TBIT/Pixabay)

2 May 2016. At a press event in Washington, D.C. last week, Representative Lloyd Doggett of Texas, a champion of lower prescription drug prices, took aim at drug companies and their business practices. “An unaffordable drug is 100 percent ineffective,” Doggett told an audience at Center for American Progress on 26 April. He . . . → Read More: Drug Pricing Reform Even Big Pharma Might Like

U.S. Energy Use Declines in 2015, Renewables Gain

(DoDLive.mil)

20 April 2016. Energy use by Americans in their homes and businesses declined in 2015 from the previous year, due to a sharp drop in coal burned for electric power, among other factors. The findings were published in an annual accounting of national energy supply and demand by Lawrence Livermore National Laboratory, based . . . → Read More: U.S. Energy Use Declines in 2015, Renewables Gain

Many Clinical Trial Protocol Changes Avoidable, Costly

(Wesley Wilson, Pexel

12 April 2016. When clinical trials make changes in plans, known as protocol amendments, after they’re underway, the impact in time and costs are substantial, with many changes considered avoidable. These are conclusions of a review of clinical trial protocol amendments carried out by Center for the Study of Drug Development . . . → Read More: Many Clinical Trial Protocol Changes Avoidable, Costly